Caris Life Sciences (CAI) vs GRAIL (GRAL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
GRAIL (GRAL) has outperformed Caris Life Sciences (CAI) over the past year, gaining 111.6% versus a loss of 16.5%. Caris Life Sciences is the larger company by market cap ($7.77 billion vs $5.92 billion), about 1.3 times the size. Caris Life Sciences converts more of its revenue into profit, with a net margin of -8.4% versus -277.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAI | GRAL |
|---|---|---|
| Share price | $27.50 | $132.61 |
| Market cap | $7.77B | $5.92B |
| 1-day change | +1.48% | -0.22% |
| YTD return | +1.93% | +55.28% |
| 1-year return | -16.54% | +111.56% |
| P/E ratio (TTM) | 16.27 | — |
| Forward P/E | 74.69 | — |
| EPS (TTM) | $1.69 | $-9.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $812.03M | $147.17M |
| Revenue growth (YoY) | +96.97% | +17.18% |
| Net income (latest FY) | $-68.09M | $-408.35M |
| Operating margin | 5.56% | -381.98% |
| Net margin | -8.38% | -277.47% |
| 52-week high | $33.65 | $166.48 |
| 52-week low | $14.19 | $41.50 |
| Distance from 52-week high | -18.28% | -20.34% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +5.75% | -15.24% |
| Average volume | 4.93M | 940.82K |
| Shares outstanding | 282.68M | 44.67M |
| Employees | 1,846 | 910 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GRAL has outperformed CAI by 128.1 percentage points over the past year.
- Caris Life Sciences is more profitable, keeping -8.4 cents of every revenue dollar as net income versus -277.5 cents for GRAIL.
- Caris Life Sciences grew revenue faster in its latest fiscal year (+96.97% vs +17.18%).
About Caris Life Sciences
CAI stock →Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms.
Health Care · Medical Specialities · 1,846 employees
About GRAIL
GRAL stock →GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer.
Health Care · Medical Specialities · 910 employees
CAI vs GRAL FAQ
Which is bigger, Caris Life Sciences or GRAIL?
Caris Life Sciences (CAI) is larger, with a market capitalization of $7.77B compared with $5.92B for GRAIL (GRAL).
Which stock has performed better over the past year, CAI or GRAL?
GRAL returned +111.56% over the past 12 months, compared with -16.54% for CAI (price return, excluding dividends). Past performance does not predict future results.
Are Caris Life Sciences and GRAIL in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.